NepalTuberculosis profile
Population  2016 29 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6.5 (4.6–8.7) 22 (16–30)
Mortality (HIV+TB only) 0.27 (0.15–0.44) 0.95 (0.5–1.5)
Incidence  (includes HIV+TB) 45 (39–50) 154 (136–174)
Incidence (HIV+TB only) 0.95 (0.52–1.5) 3.3 (1.8–5.2)
Incidence (MDR/RR-TB)** 1.5 (0.91–2.1) 5.1 (3.1–7.1)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 2.7 (2.3–3) 14 (13–16) 17 (15–19)
Males 3 (2.6–3.3) 25 (22–28) 28 (24–31)
Total 5.6 (4.9–6.3) 39 (34–44) 45 (39–50)
TB case notifications, 2016  
Total cases notified 32 056
Total new and relapse 31 371
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 18%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 75%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 70% (62–80)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.15 (0.11–0.21)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 255 4%
          - on antiretroviral therapy 227 89%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  900
(540–1 300)
Estimated % of TB cases with MDR/RR-TB 2.2% (0.98–3.4) 15% (6.7–24)  
% notified tested for rifampicin resistance 2% 33% 1 697
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 134, XDR-TB: 403
Patients started on treatment **** MDR/RR-TB: 386, XDR-TB: 17
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 92% 32 459
Previously treated cases, excluding relapse, registered in 2015 88% 1 124
HIV-positive TB cases registered in 2015 9% 179
MDR/RR-TB cases started on second-line treatment in 2014 70% 286
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 17
Funding source: 59% domestic, 41% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-01-18 Data: www.who.int/tb/data